Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Bone. 2019 Oct 21;131:115084. doi: 10.1016/j.bone.2019.115084

Table 2.

Mean (± 1 SE) values for periosteal and endosteal MS/BS, MAR and BFR rates.

Lrp5+/+;Colla2G610C/+ Lrp5A214V/+;Col1a2G610C/+
13C4 Control Antibody 1D11 TGFβ Antibody 13C4 Control Antibody 1D11 TGFβ Antibody
N = 8 7 8 8
Periosteal MS/BS (%) 51.28 (4.50) 43.22 (4.94) 40.26 (4.50) 55.53 (4.54)*
Perisoteal MAR (μm/day) 0.85 (0.11) 0.75 (0.12) 0.79 (0.11) 0.88 (0.11)
Periosteal BFR (μm3/μm2/year) 0.48 (0.07) 0.33 (0.07) 0.32 (0.07) 0.49 (0.07)
Endosteal MS/BS (%) 89.36 (3.46) 96.85 (3.80) 99.65 (3.46) 103.05 (3.49)
Endosteal MAR (μm/day) 1.29 (0.09) 1.04 (0.10) 0.96 (0.09) 1.07 (0.09)
Endosteal BFR (μm3/μm2/year) 1.15 (0.09) 1.01 (0.10) 0.98 (0.09) 1.11 (0.09)
*

p < 0.05 when compared to mice of the same genotype receiving control antibody. While most measures were not significant, there was one measure that showed a significant increase in bone formation in OI + HBM mice treated with TGFB neutralizing antibody at the periosteal surface.